Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yu Tze Ng

Neurology with Special Qualifications in Child Neurology Overland Park, KS Medical Doctor

NPI 1215041942 CMS profile 9413

12200 W 106Th St Ste 400, Overland Park, KS 66215

Open in the dashboard

General payments

$92,338

202 records reported · program years 2019–2025

Research payments

$2,300

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$285,115 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Yu Tze Ng of Overland Park, KS is reported in the CMS Open Payments database as having received $92,338 across 202 general payments and $2,300 in research payments paid to them. Separately, studies naming them as principal investigator received $285,115 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $423 12
2024 General $10,176 28
2023 General $501 9
2022 General $461 8
2022 Research $2,300 1
2021 General $2,031 9
2020 General $8,623 22
2019 General $70,124 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yu Tze Ng
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Yu Tze Ng were reported at $423. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Yu Tze Ng Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $70,124 $262 $68–$1,313 $163
2020 $8,623 $188 $46–$1,222 $114
2021 $2,031 $183 $45–$1,356 $132
2022 $461 $229 $72–$1,177 $149
2023 $501 $269 $93–$1,195 $160
2024 $10,176 $300 $98–$1,428 $164
2025 $423 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Greenwich Biosciences, Inc. $29,955 36 payments
  2. Eisai Inc. $22,441 33 payments
  3. Aquestive Therapeutics, Inc. $19,976 39 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $9,330 13 payments
  5. SK Life Science, Inc. $5,943 15 payments
  6. LivaNova USA, Inc. $1,706 18 payments
  7. Monteris Medical Corporation $863 7 payments
  8. UCB, Inc. $627 10 payments
  9. Marinus Pharmaceuticals, Inc. $351 3 payments
  10. Jazz Pharmaceuticals Inc. $230 9 payments
  11. Other $915 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51,632 22 payments
  2. Consulting Fee $16,186 4 payments
  3. Travel and Lodging $11,789 53 payments
  4. Food and Beverage $8,232 122 payments
  5. Honoraria $4,500 1 payment
Products named General payments · program years 2019–2025
  1. Epidiolex $30,186 45 payments
  2. Fycompa $22,441 33 payments
  3. SYMPAZAN $19,913 38 payments
  4. XCOPRI $5,497 7 payments
  5. VNS Therapy $1,261 11 payments
  6. Neuroblate $863 7 payments
  7. ZTALMY $351 3 payments
  8. Cenobamate $334 7 payments
  9. Briviact $324 6 payments
  10. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $284 4 payments
  11. Other $1,247 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. UCB, Inc. $2,300 1 payment

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record